Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Comparison of the acetylation of procainamide and sulfadimidine in man

  • 21 Accesses

  • 19 Citations

Summary

The acetylation of procainamide and sulfadimidine has been measured simultaneously in plasma and urine in 20 healthy human volunteers by a specific G.L.C. method, after single and multiple oral doses of procainamide retard tablets. A distinct bimodality (9 rapid and 11 slow acetylators) was apparent from the concentrations of procainamide and N-acetylprocainamide both in urine and plasma, which was in complete agreement with data about sulfadimidine acetylation. The influence of acetylator phenotype on the relative concentrations of procainamide and N-acetylprocainamide in plasma as compared to their appearance with time in urine was further studied in 5 additional healthy subjects after a single oral dose of procainamide. The present results show that acetylator phenotype can now be determined using procainamide as the test substance, and for this purpose multiple doses offer hardly any advantage over a single dose of the drug. However, because the separation between rapid and slow acetylators is less pronounced for procainamide than for sulfadimidine, precise criteria must be established for the conditions of the test, and the influence of diseases, such as renal insufficiency, should be taken into consideration.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Dreyfuss, J., Bigger, J.T., Cohen, A.I., Schreiber, E.C.: Metabolism of procainamide in rhesus monkey and man. Clin. Pharmacol. Ther.12 366–371 (1972)

  2. 2.

    Karlsson, E., Molin., L., Norlander., B., Sjöqvist, F.: Acetylation of procaine amide in man studied with a new gas chromatographic method. Brit. J. clin. Pharmacol.1 467–475 (1975)

  3. 3.

    Drayer, D.E., Reidenberg, M.M., Sevy, R.W.: N-Acetylprocainamide: An active metabolite of procainamide. Proc. Soc. exp. Biol. (N.Y.)146 358–363 (1974)

  4. 4.

    Elson, J., Strong., J.M., Atkinson., A.J. Jr.: Antiarrhythmic potency of N-acetylprocainamide. Clin. Pharmacol. Ther.17 134–140 (1975)

  5. 5.

    Frislid, K., Bredesen, J.E., Lunde, P.K.M.: Fluorimetric or gas liquid chromatographic determination of procainamide? Clin. Chem.,21 1180–1181 (1975)

  6. 6.

    Karlsson, E., Molin, L.: Polymorphic acetylation of procaine amide in healthy subjects. Acta med. scand.197 299–302 (1975)

  7. 7.

    Gibson, T.P., Matusik, J., Matusik, B., Nelson, H.A., Wilkinson, J., Briggs, W.A.: Acetylation of procainamide in man and its relationship to isonicotinic acid hydrazide acetylation phenotype. Clin. Pharmacol. Ther.17 395–399 (1975)

  8. 8.

    Karlsson, E., Åberg, G., Collste, P., Molin, L., Sjöqvist, F.: Acetylation of procaine amide in man. A preliminary communication. Europ. J. clin. Pharmacol.8 79–81 (1975)

  9. 9.

    Gibson, T.P., Lowenthal, D.T., Nelson, H.A., Briggs, W.A.: Elimination of procainamide in end stage renal failure. Clin. Pharmacol. Ther.17 321–329 (1975)

  10. 10.

    Hansteen, V., Landmark, K.H., Fremstad, D., Dahl, S.G., Jacobson, S., Marthinsen, A.Aa., Waaler, T., Frislid, K., Lunde, P.K.M.: Maintenance therapy with a new retard tablet preparation of procainamide. Amer. Heart J., in press (1975)

  11. 11.

    Strong, J.M., Dutcher, J.S., Lee, W.-K., Atkinson, A.J. Jr.: Pharmacokinetics in man of the N-acetylated metabolite of procainamide. J. Pharmacokinet. Biopharm., in press (1975)

  12. 12.

    Koch-Weser, J.: Pharmacokinetics of procainamide in man. In: Drug metabolism in man (Ed. E.S. Vesell). Ann. N. Y. Acad. Sci.179 370–382 (1971)

  13. 13.

    Graffner, C., Johnsson, G., Sjögren, J.: Pharmacokinetics of procainamide intravenously and orally as conventional and slow release tablets. Clin. Pharmacol. Ther.17 414–423 (1975)

  14. 14.

    Kosowsky, B.D., Taylor, J., Lown, B., Ritchie, R.F.: Long-term use of procainamide following acute myocardial infarction. Circulation47 1204–1210 (1973)

  15. 15.

    Evans, D.A.P.: An improved and simplified method of detecting the acetylator phenotype. J. med. Genet.6 405–407 (1969)

  16. 16.

    Fremstad, D., Dahl, S.G., Jacobson, S., Lunde, P.K.M., Nådland, K.J., Marthinsen, A.Aa., Waaler, T., Landmark, K.H.: A new sustained release tablet formulation of procainamide. Europ. J. clin. Pharmacol.6 251–255 (1973)

  17. 17.

    Atkinson, A.J. Jr., Parker, M., Strong, J.: Rapid gas chromatographic measurement of plasma procainamide concentration. Clin. Chem.18 643–646 (1972)

  18. 18.

    Refsum, H., Frislid, K., Lunde, P.K.M., Landmark, K.H.: Effects of N-acetylprocainamide as compared with procainamide in isolated rat atria. Europ. J. Pharmacol.33 47–52 (1975)

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Frislid, K., Berg, M., Hansteen, V. et al. Comparison of the acetylation of procainamide and sulfadimidine in man. Eur J Clin Pharmacol 9, 433–438 (1976). https://doi.org/10.1007/BF00606561

Download citation

Key words

  • Procainamide
  • N-acetylprocainamide
  • sulfadimidine
  • acetylated sulfadimidine
  • plasma and urinary concentration ratios
  • acetylator phenotype